tradingkey.logo
tradingkey.logo
Search

CORRECTED-Lexicon expects delay in FDA feedback on additional data for its diabetes drug

ReutersSep 22, 2025 8:38 PM
facebooktwitterlinkedin

- Lexicon Pharmaceuticals LXRX.O said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI